COLL
Price
$23.53
Change
-$0.17 (-0.72%)
Updated
Sep 4 closing price
Capitalization
766.03M
59 days until earnings call
Intraday BUY SELL Signals
LFCR
Price
$4.40
Change
+$0.05 (+1.15%)
Updated
Sep 4 closing price
Capitalization
166.55M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

COLL vs LFCR

COLL vs LFCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
COLL vs. LFCR commentary
Sep 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COLL is a StrongBuy and LFCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2026
Stock price -- (COLL: $23.53 vs. LFCR: $4.40)
Brand notoriety: COLL and LFCR are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: COLL: 139% vs. LFCR: 194%
Market capitalization -- COLL: $766.03M vs. LFCR: $166.55M
COLL [@Pharmaceuticals: Generic] is valued at $766.03M. LFCR’s [@Pharmaceuticals: Generic] market capitalization is $166.55M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

COLL’s FA Score shows that 0 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • COLL’s FA Score: 0 green, 5 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

COLL’s TA Score shows that 4 TA indicator(s) are bullish while LFCR’s TA Score has 2 bullish TA indicator(s).

  • COLL’s TA Score: 4 bullish, 6 bearish.
  • LFCR’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, COLL is a better buy in the short-term than LFCR.

Price Growth

COLL (@Pharmaceuticals: Generic) experienced а -7.18% price change this week, while LFCR (@Pharmaceuticals: Generic) price change was -3.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.17%. For the same industry, the average monthly price growth was +0.32%, and the average quarterly price growth was +36.80%.

Reported Earning Dates

COLL is expected to report earnings on Nov 05, 2026.

LFCR is expected to report earnings on Nov 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.17% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
COLL($766M) has a higher market cap than LFCR($167M). LFCR has higher P/E ratio than COLL: LFCR (51.23) vs COLL (18.51). LFCR YTD gains are higher at: -46.210 vs. COLL (-49.179). COLL has higher annual earnings (EBITDA): 388M vs. LFCR (-8.81M). COLL has more cash in the bank: 129M vs. LFCR (17.2M). LFCR has less debt than COLL: LFCR (155M) vs COLL (1.1B). COLL has higher revenues than LFCR: COLL (808M) vs LFCR (129M).
COLLLFCRCOLL / LFCR
Capitalization766M167M459%
EBITDA388M-8.81M-4,403%
Gain YTD-49.179-46.210106%
P/E Ratio18.5151.2336%
Revenue808M129M626%
Total Cash129M17.2M750%
Total Debt1.1B155M708%
FUNDAMENTALS RATINGS
COLL vs LFCR: Fundamental Ratings
COLL
LFCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
89100
SMR RATING
1..100
50100
PRICE GROWTH RATING
1..100
8879
P/E GROWTH RATING
1..100
945
SEASONALITY SCORE
1..100
4950

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (89) in the Industrial Specialties industry. This means that COLL’s stock grew somewhat faster than LFCR’s over the last 12 months.

COLL's Profit vs Risk Rating (89) in the Pharmaceuticals Other industry is in the same range as LFCR (100) in the Industrial Specialties industry. This means that COLL’s stock grew similarly to LFCR’s over the last 12 months.

COLL's SMR Rating (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that COLL’s stock grew somewhat faster than LFCR’s over the last 12 months.

LFCR's Price Growth Rating (79) in the Industrial Specialties industry is in the same range as COLL (88) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew similarly to COLL’s over the last 12 months.

LFCR's P/E Growth Rating (5) in the Industrial Specialties industry is significantly better than the same rating for COLL (94) in the Pharmaceuticals Other industry. This means that LFCR’s stock grew significantly faster than COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
COLLLFCR
RSI
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
68%
Bearish Trend 4 days ago
76%
MACD
ODDS (%)
Bearish Trend 4 days ago
60%
Bearish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 13 days ago
70%
Bullish Trend 13 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 7 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
67%
Bearish Trend 4 days ago
87%
Aroon
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
COLL
Daily Signal:
Gain/Loss:
LFCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ODVIX42.090.31
+0.74%
Invesco Developing Markets R6
AXVNX22.670.11
+0.49%
Acclivity Small Cap Value N
NDVUX18.850.09
+0.48%
MFS New Discovery Value R4
CWVCX22.880.03
+0.13%
Calvert International Equity C
DILAX17.520.02
+0.11%
Davis International A

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with EBS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then EBS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-0.72%
EBS - COLL
41%
Loosely correlated
-0.32%
ANIP - COLL
40%
Loosely correlated
-1.06%
VTRS - COLL
37%
Loosely correlated
-0.35%
AMRX - COLL
35%
Loosely correlated
-2.41%
AMPH - COLL
35%
Loosely correlated
-2.77%
More

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+1.15%
SHPH - LFCR
31%
Poorly correlated
+0.57%
COLL - LFCR
28%
Poorly correlated
-0.72%
PAHC - LFCR
27%
Poorly correlated
-0.86%
TLRY - LFCR
27%
Poorly correlated
-0.66%
VTRS - LFCR
25%
Poorly correlated
-0.35%
More